Lakes Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$31,834	12
2023	Research	$315,604	13
2022	Research	$123,282	6
2021	Research	$20,952	7
2020	Research	$7,325	4
2019	Research	$1,582	2

Breakdown

Who paid Research payments · program years 2019–2024

Merck Sharp & Dohme Corporation $322,584 4 payments
Novartis Pharmaceuticals Corporation $108,264 21 payments
Ucb SA $46,744 8 payments
Apellis Pharmaceuticals, Inc. $16,130 4 payments
Swedish Orphan Biovitrum AB $5,145 3 payments
Pfizer Inc. $1,713 4 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older $322,584 4 payments
Multicenter, Randomized, Parallel Group, Double Blind, Placebo-Controlled (12 17 Years) Including A Single Open Label Arm (6 11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol (CZP) in Pediatric Stu $39,044 6 payments
A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb10 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan $36,136 4 payments
A Single Arm Multicenter Nilotinib Treatment Free Remission Study in Patients With BCR Abl1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease MRD Status on First Line Nilotinib Treatment $26,780 9 payments
Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $19,906 2 payments
Pegcetacoplan Long Term Safety and Efficacy Extension Study $16,130 4 payments
An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PNH Phase 2 and Phase3 Studies With Iptacopan $15,562 4 payments
A Randomized, Multicenter, Active-Comparator Controlled, Open-Label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Lnp023 in Adult Patients With PNH and Residual Anemia, Despite Treatment With An Intravenous Anti-C5 Antibody. $9,881 2 payments
Multicenter, Randomized, Parallel Group, Double Blind, Placebo-Controlled (12 17 Years) Including A Single Open Label Arm (6 11 Years) Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of C $4,500 1 payment
Sobi.Pegcet-110 $3,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.